Delving into the Latest Updates on Oxfendazole with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(5-(phenylsulfinyl)-1H-benzimidazol-2-yl)carbamic acid methyl ester, 5-(phenylsulfinyl)-2-benzimidazolecarbamic acid methyl ester, 5-phenylsulfinyl-2-carbomethoxyaminobenzimidazole

+ [8]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesNervous System DiseasesOther Diseases+ [3]

Active Indication

NeurocysticercosisFascioliasisTrichuriasis+ [3]

Inactive Indication-

Originator Organization

National Institute of Allergy & Infectious Diseases

Active Organization

The Oxfendazole Development Group

Drugs for Neglected Diseases initiativeUniversidad Peruana Cayetano Heredia

+ [1]

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC15H13N3O3S

InChIKeyBEZZFPOZAYTVHN-UHFFFAOYSA-N

CAS Registry53716-50-0

Randomized clinical trial comparing the efficacy and safety of oxfendazole at 20 mg/kg per dose in one and two dose regimens with a two-dose regimen of triclabendazole at 10 mg/kg in an endemic region of the highlands of Peru. Children and adults with fascioliasis in rural communities will be screened for inclusion and exclusion criteria and a total of 336 subjects (112 per study arm) with chronic Fasciola infection will be enrolled and assigned randomly to the study arms in a 1:1:1 ratio. The primary efficacy (cure and egg reduction) endpoints will be assessed on day 7 and 30 post treatment. The secondary safety endpoint visits will be performed in days 0, 3, 7 and 30 post-treatment and Population Pharmacokinetics (PK) modeling studies will be performed in the first 24 hours after the first dose of oxfendazole.

Start Date30 Jan 2025

Sponsor / Collaborator

Universidad Peruana Cayetano Heredia

[+2]

NCT06565507 / Not yet recruitingPhase 2/3IIT

A Double-blind Multicenter, Randomized Controlled Trial of Single and Multiple Dose Regimens of Oxfendazole for Mild (One or Two Lesions) Parenchymal Brain Cysticercosis, With an Open Comparison Group

The goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cisticercosis. The main question it aims to answer is if OXF will enhance clearance of brain parasites and therefore provide greater cysticidal efficacy, with the potential to provide a single-dose therapy for this type of NCC.
The study cohort will also allow us to identify early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution. This study will also provide additional information on the safety of the study interventions.

Start Date15 Dec 2024

Sponsor / Collaborator

Universidad Peruana Cayetano Heredia

[+1]

NCT03435718 / Not yet recruitingPhase 2IIT

An Assessor Blind, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults

The main objective of this study is to provide data on the efficacy profile of different doses of oxfendazole when used in Trichuris trichiura infection. The drug will be also be examined for efficacy against other common nematodes encountered in man (Ascaris lumbricoides, Ancylostoma duodenale, Necator americanus). The study will also provide data on the safety and tolerability of the oxfendazole in patients.

Start Date01 Jul 2024

Sponsor / Collaborator

The Oxfendazole Development Group

[+1]

100 Clinical Results associated with Oxfendazole

Login to view more data

100 Translational Medicine associated with Oxfendazole

Login to view more data

100 Patents (Medical) associated with Oxfendazole

Login to view more data

1,595

Literatures (Medical) associated with Oxfendazole

06 Dec 2024·Journal of Biomolecular Structure and Dynamics

Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer

Article

Author: Nidhi ; Khan, Imran A. ; Khan, Mohd Ashif ; Reeta ; Garg, Aakriti ; Karhana, Sonali ; Bano, Aysha

Emerging studies have reported the potential anticancer activity of benzimidazole-based anthelmintics (BBA) against lung cancer (LC). However, mechanism underlying the anticancer activity of BBA is unclear. Therefore, in the current study, network pharmacology and molecular docking-based approach were used to explore the potential molecular mechanism for the treatment of LC. The potential targets for BBA were obtained from multiple databases including SwissTargetPrediction, Drug Bank, Therapeutic Target Database, and Comparative Toxicogenomics Database while LC targets were collected from DisGeNet gene discovery platform, Integrated Genomic Database of NSCLC, Catalogue of Somatic Mutations in Cancer and Online Mendelian Inheritance in Man database. Protein-protein interaction (PPI) diagram of common targets was constructed using STRING online platform. Topological analysis was performed using Cytoscape and gene enrichment analysis was conducted using FunRich software. Highest degree targets were then confirmed using molecular docking and molecular dynamics simulations. The BBA were prioritized according to their S scores, with ricobendazole ranking highest followed by flubendazole, fenbendazole, mebendazole, triclabendazole, albendazole, oxibendazole, parbendazole, thiabendazole and oxfendazole. The potential targets of BBA identified using topological analysis and molecular docking were found to be CCND1 (cyclin D1), EGFR (Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2/CD340), PTGS2 (Prostaglandin-endoperoxide synthase 2), and SRC (Proto-oncogene tyrosine-protein kinase). Furthermore, molecular dynamics confirmed that CCND1 and EGFR are the potential targets of ricobendazole for the treatment of LC. BBA can be further explored as a therapeutic strategy for the treatment of lung cancer under in vitro and in vivo studies.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·International Journal for Parasitology: Parasites and Wildlife

Response of Northern bobwhite (Colinus virginianus) and two parasitic nematode populations in western Oklahoma to anthelmintic supplemental feed

Review

Author: Kendall, Ronald J. ; Lukashow-Moore, Shannon P. ; Suber, Hannah N. ; Suber, Hannah N ; Conley, Katelyn A. ; Conley, Katelyn A ; Rivera, Regan ; Surles, James G. ; Surles, James G ; Lukashow-Moore, Shannon P ; Leach, Jeremiah ; Kendall, Ronald J

It has been demonstrated that helminths are capable of critically impacting the fitness of their hosts. This has typically been shown experimentally through the administration of anthelmintic drugs but are rarely performed on a landscape or host population scale. Here, the anthelmintic fenbendazole (FBZ) was mixed in a supplemental feed and provided to a free-ranging population of Northern bobwhite quail (Colinus virginianus). Abundances of Northern bobwhite and two nematode parasites commonly found infecting Northern bobwhite were monitored and compared to a neighboring untreated population. The Northern bobwhite population receiving the medicated feed grew substantially from 2019 to 2022, while the neighboring site had no change in abundance. The treated population was also substantially greater than the untreated population in 2021 and 2022. Additionally, the treated Northern bobwhite population had substantially lower abundances of the two nematodes. This research provides evidence of the ability of helminth populations to have a negative impact on Northern bobwhite populations and presents a method for reducing helminth abundance in those populations on a landscape scale.

01 Dec 2024·International Journal for Parasitology: Parasites and Wildlife

Identification and management of infections caused by Giardia sp., Trichuris sp. and Demodex sp. in captive Brazilian porcupines (Coendou prehensilis)

Article

Author: Frey, Caroline F ; Frey, Caroline F. ; Moré, Gastón ; Gliga, Diana S ; Rüegg-van den Broek, Peggy ; Glardon, Olivier J ; Basso, Walter ; Gliga, Diana S. ; Glardon, Olivier J.

The Brazilian porcupine (Coendou prehensilis, Rodentia, Erethizontidae) is an arboreal South American nocturnal rodent. Switzerland is home to one of the largest captive colonies in Europe. In June 2022, most of the animals in this colony showed severe diarrhoea, and Giardia sp. cysts were detected. All the animals were treated with metronidazole (75 mg/animal/day orally) for five days, repeating after two weeks. The diarrhoea continued, sometimes containing blood, and further analyses revealed Giardia sp. cysts and Trichuris sp. eggs with a particular undulating eggshell in pooled samples. The soil layer of some enclosures was removed to thoroughly clean and disinfect the underlying concrete floor. The animals were treated with fenbendazole (50 mg/kg/day orally) for 5 days repeating after three days. Giardia sp. cysts were not further detected. However, Trichuris sp. eggs were detected in branch bark samples and in six animals 2-3 months after treatment. The treatment with fenbendazole was repeated and no further Trichuris sp. eggs were detected. A 18S rRNA fragment consensus sequence showed 98.58% identity with Trichuris fossor. The Trichuris sp. in C. prehensilis may represent a new species, specific for arboreal porcupines. Demodex mites were observed in faecal flotations and thereafter in skin scrapings from five animals (four of them being family-related). A 16S consensus sequence showed 86.4% identity with other Demodex species. The animals were initially treated with moxidectin (0.4 and 0.8 mg/kg orally) and afterwards with sarolaner (10 mg/animal) but the treatments were not completely effective since in control scrapings, two animals evidenced few non-motile mites. An individual susceptibility and poor immunological control of the infection is suggested. Treatment with fenbendazole was effective against Giardia sp. and Trichuris sp. infections; however, reinfections may occur if the enclosures and tree branches are not deep cleaned and disinfected or replaced.

100 Deals associated with Oxfendazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D05291	Oxfendazole	-	DB11446

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neurocysticercosis	Phase 3	-	Universidad Peruana Cayetano Heredia	15 Dec 2024
Neurocysticercosis	Phase 3	-	The Oxfendazole Development Group	15 Dec 2024
Fascioliasis	Phase 2	-	National Institute of Allergy & Infectious Diseases	30 Jan 2025
Trichuriasis	Phase 2	-	The Oxfendazole Development Group	01 Jul 2024
Filariasis	Phase 1	TZ	Drugs for Neglected Diseases initiative	21 Apr 2022
Onchocerciasis, Ocular	Phase 1	CH	Drugs for Neglected Diseases initiative	30 Jan 2022
Helminthiasis	Phase 1	US	The Oxfendazole Development Group	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03035760 (CTgov)	Phase 1	Helminthiasis	36	Oxfendazole (Arm 1: 3 mg/kg Oxfendazole for 5 Days)	szwzmanmoh(drrklgpduw) = mzfotmapvb rlxljtvifk (vbujgzsvhm, tcwlynogvg - jzzidixehv) View more	-	17 Dec 2019
				Oxfendazole (Arm 2: 7.5 mg/kg Oxfendazole for 5 Days)	szwzmanmoh(drrklgpduw) = fjltoyiwgi rlxljtvifk (vbujgzsvhm, xokdgdoxhl - zsvknqofac) View more
NCT02234570 (CTgov)	Phase 1	Neurocysticercosis	70	Oxfendazole (0.5 mg/kg Oxfendazole)	nxjulrtgej(jedhfdkoeb) = mzfijkvlij maheuvhovb (ppmwgpwomh, ymftohdwvx - zhlotwdeww) View more	-	26 Nov 2019
				Oxfendazole (1 mg/kg Oxfendazole)	nxjulrtgej(jedhfdkoeb) = vmykfbzqjk maheuvhovb (ppmwgpwomh, whidlvnxcp - wdwaipgqfl) View more
NCT02234570 (Pubmed \| Antimicrob Agents Chemother)	Phase 1	-	70	Oxfendazole	(epofcmuypi) = dose-dependent decrease iremlgzbif (irpydlzxzw ) View more	-	01 Apr 2019